COMP <GO>
BDX vs MRK // EV/EBITDA & P/E VALUATION
Becton Dickinson and Company (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BDX 4
— MRK 11
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $197.88 (-0.23%) • MKT CAP: $54.03B
valuation
21.8x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BDX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.40% | 74.80% | -29.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.90% | 20.70% | -15.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.8x | 15.3x | +6.50 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 3.42% | -1.29 | MRK | /fcf-yield <GO> |
| Operating Margin | 11.80% | 34.30% | -22.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 28.10% | -20.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.20% | 1.30% | +6.90 | BDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.21% | 2.26% | -0.05 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 5.19 | -2.97 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.0 | 56.9 | +7.15 | BDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.92 | +0.14 | BDX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.9x | 18.4x | +11.50 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.03B | $361.02B | -$307.00B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BDX REV | MRK REV | BDX GROSS % | MRK GROSS % | BDX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.84B | $65.01B | 45.4% | 74.8% | $1.12B | $12.36B |
| FY 2024 | $20.18B | $64.17B | 45.2% | 76.3% | $1.18B | $18.10B |
| FY 2023 | $19.37B | $60.12B | 44.0% | 44.0% | $790.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDX // BETA 1.06
MRK // BETA 0.92